beta-2'-deoxythioguanosine

10/01/1977 - "Phase II Study of beta-2'-deoxythioguanosine in adult acute leukemia."
06/01/1985 - "Phase I evaluation of beta-2'-deoxythioguanosine in pediatric patients with leukemia."
02/01/1979 - "Treatment of refractory adult acute leukemia with 5-azacytidine plus beta-2'-deoxythioguanosine."
08/01/1977 - "Combination therapy with 5-azacytidine plus beta-2'-deoxythioguanosine in adult acute leukemia."
06/01/1985 - "Thirty-one pediatric patients with acute leukemia who had relapsed on either 6-mercaptopurine or 6-thioguanine were treated with beta-2'-deoxythioguanosine, which was administered as an iv infusion every 12 hours for three or six doses every 2 weeks. "

01/01/1982 - "However, a new agent, beta-2'-deoxythioguanosine (beta-TGdR) can overcome TG resistance in animal tumor models and is therefore of potential clinical use. "
05/01/1975 - "Lack of activity of beta-2'-deoxythioguanosine against two tumors resistant to 6-thioguanine."
06/01/1985 - "Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and beta-2'-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas. "
06/01/1985 - "Phase II trials of several single agents demonstrated only minimal objective response rates in patients with pancreatic carcinoma and measurable tumors: hexamethylmelamine (7%; four responses among 55 patients); dianhydrogalactitol (2.5%; one response among 40 patients); razoxane (7%; two responses among 29 patients); and beta-2'-deoxythioguanosine (6%; two responses among 32 patients). "
01/01/1976 - "Beta-thioguanine deoxyriboside (betaTGdR) is a purine nucleoside derivative which was studied alone or in combination with arabinosyl cytosine (Ara-C) in patients with solid tumors and acute leukemia. "

08/01/1979 - "Phase II evaluation of diglycoaldehyde, VP-16-213, and the combination of methyl-CCNU and beta-2'-deoxythioguanosine in previously treated patients with colorectal cancer: an Eastern Cooperative Oncology Group study (EST-1275)."
08/01/1979 - "The Eastern Cooperative Oncology Group assessed the activity of diglycoaldehyde (DGA), VP-16-213, and the combination of methyl-CCNU and beta-2'-deoxythioguanosine in previously treated patients with advanced colorectal cancer. "
01/01/1981 - "Two hundred twenty eligible patients with metastatic colorectal carcinoma were treated with a combination of beta-2'-deoxythioguanosine (BTG), plus methyl-CCNU or mitomycin. "
01/01/1981 - "Evaluation of beta-2'-deoxythioguanosine combined with methyl-CCNU or mitomycin in advanced colorectal cancer. "

06/01/1985 - "Phase II trials of several single agents demonstrated only minimal objective response rates in patients with pancreatic carcinoma and measurable tumors: hexamethylmelamine (7%; four responses among 55 patients); dianhydrogalactitol (2.5%; one response among 40 patients); razoxane (7%; two responses among 29 patients); and beta-2'-deoxythioguanosine (6%; two responses among 32 patients). "

12/01/1978 - "Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2-chlorethyl)-1-nitrosourea: a Phase II-III study of the Eastern Cooperative Oncology Group (EST 4273)."